Scientist/ Sr Scientist, NK CAR Cell Therapy for Solid Tumors at Senti Biosciences
South San Francisco, CA, US
Thank you for your interest in a career at Senti Biosciences. Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. We are passionate about designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines are unable to address.
 
At Senti, we find purpose and meaning knowing that our efforts have the potential to improve the lives of patients and their families with more effective and safer treatment options. With science as our foundation and empathy as our key guiding principle, colleagues become friends, managers become mentors, and with time, cancer becomes history.
 
Our R&D team is seeking an experienced, talented, and driven Scientist to perform and lead efforts to evaluate the efficacy and mechanism of gene circuits in combination to NK CAR-based cell therapies to address current challenges in solid tumors. The successful candidate will not only have a thorough understanding of the CAR NK/ T cell field and literature but must be comfortable designing and performing immune cell-based assays independently and working collaboratively across various project teams to meet deadline-dependent milestones. Most of all, we are looking for a curious, bold, detail-orientated, and eager Scientist to be part of a positive work environment to develop much needed novel cell therapies targeting cancer.

Responsibilities:

    • Employ expert knowledge to help lead the company’s efforts to develop next-generation Multi-Armed CAR NK cell therapies for treating cancer patients in need.
    • Independently design, execute, and troubleshoot in vitro CAR NK cell cytotoxicity and cytokine production assays, using multi-color flow cytometry, Luminex, and IncuCyte instruments.
    • Work collaboratively with fellow researchers to plan, execute, analyze, and discuss cell-based experimental strategies to validate new generation gene circuits for our NK CAR pipeline.
    • Stay current with the relevant scientific literature, and participate in ideation and decision-making meetings
    • Develop and write SOP, maintain detailed electronic lab records, and perform data analysis.
    • Collaborate with your colleagues at Senti by coordinating with other group members and research teams to troubleshoot problems, develop new assays, and support cross-functional projects
    • Provide expert support for experiment design and assay development to the broader scientific team

Qualifications:

    • Ph.D. or equivalent expertise in immunology, cancer biology, cell biology, gene therapy or related field
    • >5 years of postdoctoral or industry experience in NK cell biology, CAR-based cell therapy, or related field
    • Thorough understanding of the cell and or gene therapy landscape, with a working knowledge engineering and assaying in vitro and in vivo NK cell activity
    • Proficient in multi-color flow cytometry and FlowJo-based data analysis
    • Demonstrated ability to work independently and as part of a multi-functional team
    • Successful experience in mentoring, training, and leading a small research team
    • Excited by the challenge of working in a dynamic, flexible, and fast-paced start-up company environment
    • Motivated, detail-orientated, and eager to be part of a positive work environment with other researchers to develop next generation CAR NK cell therapies targeting cancer
Senti Bio is a leading gene circuit company designing gene circuits to create a new generation of “smarter medicines" and enhance the therapeutic effectiveness of cell and gene therapies against a broad range of diseases that are unaddressed by current standards of care. We are proud to count Leaps by Bayer, NEA, 8VC, Matrix Partners China, Mirae Asset Capital, Amgen Ventures, and others among our investors. In December 2021, Senti Bio and Dynamics Special Purpose Corp. (Nasdaq: DYNS), a special purpose acquisition company (SPAC), announced a definitive business combination agreement to create a public company focused on Gene Circuit-engineered cell and gene therapies. The transaction is expected to be completed in the second quarter of 2022. Senti Bio is based in South San Francisco, CA, USA.
 
We are committed to an inclusive and diverse Senti Bio. We believe that different perspectives lead to better ideas, and better ideas allow us to better understand the needs and interests of our diverse Senti Team. We welcome people of different backgrounds, experiences, abilities and perspectives and are an equal opportunity employer.